Luteal Support in Frozen-Thawed Embryo Transfer Cycles

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

151 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-06-30

Study Completion Date

2021-12-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the clinical efficacy of 3 different luteal phase support in patients undergoing frozen-thawed embryo transfer cycles. Endometrium preparation will be hormone replacement in all cycles. Starting from day 11, group 1 will receive 100 mg micronized progesterone parenteral daily injections, group 2 will receive 90 mg bioadhesive gel vaginal twice daily and group 3 will receive 40 mg oral dydrogesterone daily tablets.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Oral Dydrogesterone vs. Micronized Vaginal Progesterone for Luteal Phase Support in Frozen-thawed Embryo Transfer Cycles

NCT04124913

Infertility, Female Infertility, Male Embryo Transfer +5 more

UNKNOWN PHASE4

Oral Versus Vaginal Progesterone for Luteal Phase Supplementation in Frozen Embryo Transfer Cycles

NCT04758871

Frozen Embryo Transfer Hormone Replacement Therapy Dydrogesterone +1 more

COMPLETED PHASE4

Luteal Phase Support During Frozen Embryo Transfer Cycle

NCT04013438

Infertility, Female Frozen Embryo Transfer

COMPLETED PHASE3

Progesterone as Luteal Support in Frozen IVF Natural Cycles

NCT04725864

Infertility Embryo Transfer

RECRUITING PHASE4

Addition of Dydrogesterone to the Luteal Phase Support After Fresh Embryo Transfer

NCT04408144

Infertility IVF

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In natural pregnancy, successful implantation and pregnancy necessitates well-functioning corpus luteum. Luteal phase support (LPS) is critical in assisted conception cycles particularly for replacement frozen embryo transfer cycles owing to lack of corpus luteum. 3 different LPS options have been suggested:

* Progesterone in oil (intramuscular injections) is rapidly absorbed after i.m. injection and high progesterone plasma concentrations are reached after approximately 2h. Despite satisfactory plasma levels, the possible side-effects of pain and swelling are limiting the use.
* Vaginal application of progesterone is widely accepted with satisfactory endometrial levels and patient convenience. However, increased vaginal discharge and possible vaginal irritation are the most common side effects.
* Oral administration of synthetic progesterone (dydrogesterone) would offer a convenient way of progesterone administration. Better bioavailability than natural progesterone and less cost makes dydrogesterone preferable. Also, good quality evidence revealed satisfactory outcomes in fresh embryo transfer cycles. However, there is lack of good quality evidence for dydrogesterone as a LPS in frozen-thawed cycles.

The investigator's aim is to compare 3 widely used LPS in frozen-thawed embryo transfer cycles.

Following allocation of the subjects, hormone replacement will be scheduled for the endometrial preparation. Briefly; On day 2 of menstrual bleeding, endometrial preparation with oral estradiol (E2) (2 mg twice daily) will be initiated. Approximately 10 days after initiation of E2 administration, the subject will undergo a transvaginal ultrasound examination to assess endometrial development and serum progesterone (P) level will be checked. Once the subject achieved a trilaminar endometrium with a thickness of \>7 mm with serum P levels \<1.5 ng/ml, she will start the progesterone treatment to which she will be randomized to one of the 3 arms. After 3 days of P treatment along with E2 pills, cleavage embryo transfer will be performed. If the subject will receive blastocyst, 5 days of P treatment will be scheduled.

If these criteria were not met at the first evaluation, she will allowed up to 10 additional days (20 days total) of estrogen stimulation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Implantation; Placenta Pregnancy Loss Frozen Embryo Luteal Support Luteal Phase Defect Assisted Reproduction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

intramuscular progesterone

progestan (progesterone) 50 mg/ml ampoules, 2 ampoules (100 mg) intramuscular starting from day 11 of the endometrial preparation cycle.

Group Type ACTIVE_COMPARATOR

Progesterone 50Mg/mL Oil

Intervention Type DRUG

100 mg daily intramuscular injections

vaginal progesterone

crinone %8 bioadhesive gel (progesterone) 90 mg, twice daily (180 mg/day) starting from day 11 of the endometrial preparation cycle.

Group Type ACTIVE_COMPARATOR

Crinone 8% Vaginal Gel

Intervention Type DRUG

180 mg daily vaginal gels

oral dydrogesterone

oral dydrogesterone (progesterone) 10 mg tablets, 2x2 (40 mg total)

Group Type EXPERIMENTAL

Dydrogesterone 10Mg Tablet (duphaston)

Intervention Type DRUG

40 mg daily oral tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dydrogesterone 10Mg Tablet (duphaston)

40 mg daily oral tablets

Intervention Type DRUG

Progesterone 50Mg/mL Oil

100 mg daily intramuscular injections

Intervention Type DRUG

Crinone 8% Vaginal Gel

180 mg daily vaginal gels

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* woman aged 20-40 years
* Having available blastocyst(s) cryopreserved by vitrification method.

Exclusion Criteria

* requirement for fresh embryo(s);
* presence of any clinically relevant systemic disease contraindicated for assisted reproduction or pregnancy
* history of more than three failed cycles of IVF
* history of recurrent abortions
* allergy history for relevant drugs
* body mass index of \<18 or \>38 kg/m2 at screening
* current breastfeeding or pregnancy
* refusal or inability to comply with the requirements of the protocol for any reason, including scheduled clinic visits and laboratory tests
* trophectoderm or blastomere biopsy of the blastocyst(s) to be transferred

Minimum Eligible Age

20 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes